Posted by admin on Aug 12th, 2022

Texas Permanent School Fund decreased its stake in shares of NuVasive, Inc. (NASDAQ:NUVA – Get Rating) by 1.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 36,678 shares of the medical device company’s stock after selling 621 shares during the quarter. Texas Permanent School Fund owned 0.07% of NuVasive worth $2,080,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Verdence Capital Advisors LLC bought a new position in NuVasive during the first quarter valued at about $204,000. Inspire Investing LLC acquired a new position in shares of NuVasive in the first quarter valued at $236,000. Profund Advisors LLC lifted its position in NuVasive by 5.3% in the fourth quarter. Profund Advisors LLC now owns 4,723 shares of the medical device company’s stock worth $248,000 after purchasing an additional 236 shares during the period. NorthCrest Asset Manangement LLC acquired a new stake in NuVasive during the fourth quarter worth $291,000. Finally, Gotham Asset Management LLC bought a new stake in NuVasive in the 4th quarter valued at $357,000.

NUVA opened at $52.57 on Friday. NuVasive, Inc. has a 1-year low of $45.45 and a 1-year high of $64.43. The stock has a market capitalization of $2.74 billion, a PE ratio of -65.71, a PEG ratio of 2.04 and a beta of 1.14. The company has a current ratio of 1.17, a quick ratio of 0.70 and a debt-to-equity ratio of 0.54. The firm has a 50-day moving average price of $50.75 and a two-hundred day moving average price of $52.70.

Several brokerages have recently weighed in on NUVA. Truist Financial decreased their target price on shares of NuVasive to $63.00 in a research report on Friday, July 22nd. Morgan Stanley dropped their target price on NuVasive from $62.00 to $54.00 and set an “equal weight” rating for the company in a report on Friday, July 15th. Canaccord Genuity Group boosted their price target on NuVasive from $50.00 to $55.00 in a research note on Friday, August 5th. Finally, Piper Sandler dropped their price objective on NuVasive from $80.00 to $60.00 and set an “overweight” rating for the company in a research note on Thursday, August 4th. One analyst has rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, NuVasive presently has a consensus rating of “Hold” and a consensus target price of $61.75.

NuVasive, Inc, a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA – Get Rating).

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.

CNO Financial Group, Inc. (NYSE:CNO) Shares Sold by Texas Permanent School Fund

Etsy, Inc. (NASDAQ:ETSY) Shares Sold by Texas Permanent School Fund